Trial Profile
A phase I/II study of Cisplatin, Amrubicin plus irradiation for Limited disease small cell lung cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Cisplatin (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 17 Jun 2017 Status changed from recruiting to completed.
- 06 Jun 2017 Results (n=8) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 23 Jun 2011 New trial record